Psoriasis drug may affect birth control: small study investigates
NCT ID NCT07181343
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial in 18 healthy women aged 18–40 tested whether taking the experimental psoriasis drug HS-10374 changes how the body absorbs and clears the birth control pill Yasmin. Participants took Yasmin alone and then again after a course of HS-10374. Researchers measured drug levels in the blood to see if there is a meaningful interaction. The results will guide safe co-prescribing for women with psoriasis who need contraception.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-10374 tablets and drospirenone/ethinyl estradiol (Yasmin) tablets
What this could lead to
If successful, this study will show whether HS-10374 changes how the body processes Yasmin, helping doctors prescribe both safely together for women with psoriasis.
What could go wrong
This is a small, early-phase study in healthy volunteers, not patients. It only measures drug levels, not real-world effectiveness or side effects. Results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266001, China